8 Results for "

CBFβ

" in MedChemExpress (MCE) Product Catalog:
Products (8)

8 Results for "CBFβ" in MCE Product Catalog:

33
33 Publications Verification
Cat. No.: HY-16268
CAS No.: 4727-31-5
Synonyms: KGN
Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

Kartogenin (KGN) is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
loading...
    loading...
33
33 Publications Verification
Cat. No.: HY-16268A
CAS No.: 1401168-39-5
Synonyms: KGN sodium
Target:  

TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

Kartogenin (KGN) sodium is an inducer of chondrogenic tissue formation (EC50: 100 nM). Kartogenin sodium induces chondrogenesis by binding to fibrin A, disrupting its interaction with the transcription factor core binding factor beta subunit (CBFβ), and by modulating the CBFβ-RUNX1 transcriptional program. Kartogenin sodium also promotes tendon-bone junction (TBJ) wound healing by stimulating collagen synthesis. Kartogenin sodium is widely used in cell-free therapy in the field of regeneration for cartilage regeneration and protection, tendon-bone healing, wound healing and limb development. Kartogenin sodium promotes cartilage repair, coordinates limb development, and is also used in osteoarthritis (OA) research .
loading...
    loading...
13
13 Cited Publications
Cat. No.: HY-108470
CAS No.: 30195-30-3
Purity:  99.35%
Target:  

RUNX

Research Areas:  

Cancer

Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-138617
CAS No.: 1256094-31-1
Purity:  98.93%
Target:  

RUNX

Research Areas:  

Cancer

AI-10-47 is a small molecule inhibitor of CBFβ-RUNX binding, with an IC50 of 3.2 μM .
loading...
    loading...
Cat. No.: HY-124137
CAS No.: 493028-20-9
Target:  

RUNX

Research Areas:  

Cancer

Runx1-CBFβ interaction inhibitor 1 is an allosteric inhibitior of Runt domain-CBFb interaction (IC50=3.2 μM) .
loading...
    loading...
Cat. No.: HY-118365
CAS No.: 106410-13-3
Target:  

RUNX

Research Areas:  

Infection Cancer

NSC 140873 is an inhibitor of the RUNX1-CBFβ interaction. NSC 140873 can be used for research of viral infection and leukemia. NSC 140873 has an unstable structure and can be converted spontaneously in solution to a benzodiazepine (Ro5-3335) .
loading...
    loading...
Cat. No.: HY-125966
CAS No.: 63053-14-5
Target:  

RUNX

Research Areas:  

Cancer

AI-4-57 is an allosteric inhibitor for CBFβ SMMHC-RUNX1 (core binding factor β and the smooth-muscle myosin heavy chain) interaction with an IC50 of 22 μM .
loading...
    loading...
Cat. No.: HY-108470R
CAS No.: 30195-30-3
Research Areas:  

Cancer

Ro5-3335 (Standard) is the analytical standard of Ro5-3335 (HY-108470). This product is intended for research and analytical applications. Ro5-3335, a benzodiazepine, acts as an inhibitor of core binding factor (CBF) leukemia. Ro5-3335 is a RUNX1-CBFβ interaction inhibitor that represses RUNX1/CBFB-dependent transactivation .
loading...
    loading...